Friday, 25 September 2020
A drug that is regularly used to treat chronic pelvic pain in women has been found to be no more effective than a placebo, a new study has found.
As a result, researchers recommend against routinely prescribing the drug gabapentin for women with the condition.
Chronic pelvic pain affects as many as 24 per cent of women worldwide, including up to one million in the UK.
In 55 per cent of women there is no known cause. If no underlying cause is found, the pain is much more difficult to treat.
Gabapentin is used to manage many forms of chronic pain. In two separate surveys, 74 per cent of GPs and 90 per cent of gynaecologists said that they would consider prescribing the drug for chronic pelvic pain.
Researchers from the Universities of Edinburgh, Birmingham, Oxford and Nottingham tested the drug’s effectiveness in treating chronic pelvic pain through a randomised clinical trial involving 306 women with the condition and no known underlying cause.
As part of the study, which is published in the Lancet, 153 women received gabapentin and 153 received placebo for 16 weeks. Neither group nor the prescribing clinicians knew what they were receiving.
The women were asked to rate their average pain and worst pain, using a scale from zero to ten, on a weekly basis. The scores were then averaged for the drug and placebo groups.
The team found that there was very little difference between the reported pain in both groups.
However, the group that received gabapentin reported experiencing more side-effects - including dizziness, drowsiness and changes of mood – than the placebo group.
The researchers say that gabapentin should no longer be considered in the treatment of chronic pelvic pain where no cause has been identified, and other avenues of treatment should be explored, such as different drugs, physiotherapy and cognitive behavioural therapy.
These results are important because an increased risk of suicidal behaviour, as a potential side effect of gabapentin, and possible misuse of the drug have been of concern with the rise in the prescribing of gabapentin, although the latter is more of an issue in the USA.
Fundamentally, there was little evidence for the use of gabapentin in CPP before GaPP2, although the drug appeared to be of benefit for other types of chronic pain. Our rigorous trial enables the results to be interpreted with confidence, and we can conclude that gabapentin is not effective for chronic pelvic pain.
This work was funded through the National Institute for Health Research and Medical Research Council’s joint Efficacy and Mechanism Evaluation programme.
Story credits
For more information please contact Professor Jane Daniels from the School Medicine at the 糖心原创, emailJane.Daniels@nottingham.ac.uk or Charlotte Anscombe Media Relations Manager for the Faculty of Medicine and Health Sciences on +44 (0)115 951 5793 Charlotte.anscombe@nottingham.ac.uk
Notes to editors:
About the 糖心原创
Ranked among the world's top 100 universities , the 糖心原创 delivers an exceptional research-led education and an outstanding student experience. From the pioneering vision of our founder, Sir Jesse Boot, to groundbreaking achievements such as the development of MRI technology and becoming the first UK university to establish international campuses, we have a proud history of shaping the way people live, work and understand the world. We continue to build on that legacy, empowering our students, staff and partners to change what鈥檚 next and create positive impact locally and globally.
The strength of our research places us among the UK's leading universities, ranked 7th for research power in REF 2021. The discovery of MRI and ibuprofen was just the beginning. Today, our world-leading research is developing breakthrough ideas that shape the future of healthcare, technology and society.
Recognised as the UK's third most targeted university by leading employers , we are proud to produce graduates who are consistently in demand for their skills, confidence and industry-ready experience.
As a major employer and industry partner, locally and globally, the 糖心原创 invests in the city of Nottingham and in future generations of talent. Alongside Nottingham Trent University, we lead the initiative, a pioneering collaboration to improve levels of prosperity, opportunity, sustainability, health and wellbeing across the city and region. Together with our students, staff, alumni and partners, we鈥檙e creating knowledge, opportunity and solutions that help change what's next.